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This historical article review takes the reader from the 
introduction of  surgical treatment of  acute myocardial 
infarction (AMI) by the saphenous vein graft technique, 
starting in April 1968, through the progress that has been 
made to date in preventing and combatting the devastating 
effects of  AMI  and up to current reatments. 
Acute Coronary Insufficiency 
(Impending Acute Myocardial 
Infarction and Mycordial 
Infarction) Surgical Treatment by 
the Saphenous Vein Graft Technique 
by Favaloro, Efl]er, Cheanvevchai, Quint, and Sones Jr. (8) 
ABSTRACT 
The development of direct coronary artery surgery by the 
saphenous vein graft technique for the first time provides a
method that immediately increases the supply of oxygen to the 
myocardium. As a result, the area of myocardial infarction no 
longer depends only upon oxygen consumption. 
Emergency surgery was performed on 29patients from `4pril 
1968 to May 1971; 18 operations were performed upon patients 
with in~ending myocardial infarction and l l  upon patients 
with acute myocardial infarction. Nineteen patients underwent 
coronary cin'eangiography before the acute episode; 9 were 
studied during an acute episode. Patients with impending 
myocardial infarction were operated on within 24 hours of the 
acute pisode. Nine patients with acute infarction were operated 
upon within 4 to 5 hours, 2 within 8 hours and 2 within 10 
hours. Three patients died after the operation; 2 in the group 
with impending myocardial infarction and 1 in the group with 
acute infarction. Twelve patients underwent repeat cineangio- 
graphic evaluation..4# grafts but 1 were open. In the group 
with impending myocardial infarction, postoperative l ft ven- 
triculography showed good function of the left ventricle. In the 
group with acute myocardial infarction, 4patients howed good 
function of the left ventricle. In l the ventricle was unchanged, 
and in 2 impaired contraction was demonstrated. 
Although the present clinical experience is limited, certain 
conclusions can be made: (1) Emergency coronary cineangiog- 
From the Favaloro Foundation, Buenos Aires, Argentina. 
raphy can be pesrormed with minimal 14sk. (2) Patients with 
impending myocardial infarction can undergo peration with a 
low mortality rate and minimal complications. These patients 
are ideal candidates. The operation can prevent myocardial 
infarction. (3) When operations are performed within 6 hours of 
an acute myocardial infarction, most of the heart muscle can be 
preserved. (4) In patients with acute myocardial infarction and 
cardiogenic shock, assisted mechanical circulation is mandatory 
50th Anniversary Historical Article 
INTRODUCTION 
In this edition of the Journal, we release the sixth in a series of 
reviews of influential articles that have been previously pub- 
lished in ACC journals, including the ..4mericanJournal of Cardi- 
ology (from 1958 to 1982) and J.4CC (from 1983 to the present). 
The publication of these articles is only one aspect of the ACC's 
50th anniversary commemoration, which highlights 50 years of 
leadership in cardiovascular care and education. The articles are 
intended to encourage r flection on the remarkable progress made 
in cardiovascular medicine over time, as well as to acknowledge the 
amazing prescience ofsome early investigators in anticipating and, 
in many cases, later guiding developments in their field. 
The working group responsible for selecting these articles and 
asking reviewers to write editorials solicited suggestions from 
the ACC's clinical committees and individual members. 
The group achieved consensus fairly easily, including whom the 
group should ask to prepare the accompanying editorials. We 
initially drew up a list of 14 general areas to cover in this series, 
but later found that there are several major areas of modern 
cardiology, prominently molecular cardiology, in which the truly 
landmark articles have, alas, not yet been published in JACC. 
Therefore, the working group decided not to categorize by subject, 
but instead, to concentrate on the most important articles. 
The working group, a task force of the Subcommittee for the 
Commemoration f the ACC 50th Anniversary, owes a great 
deal to Ms. May A. Roustom and the efficient and tireless taff 
at Heart House for facilitating this project. We also wish to 
thank all who suggested articles and, most important, the 
authors who prepared reviews for their willingness to contribute 
their time and wisdom. 
Influential.4rtides in J/1CC Working Group 
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as the first step. The increase of well-oxygenated blood supply 
sbouM improve myocardial petfusion. 
Originally published in ~4merican Journal of Cardiology, November 1971. 
Revie,w 
During work on myocardial revascularization using the 
Vineberg approach in the early 1960s, I was puzzled by the 
discrepancy between the cfinical and pathologic findings in 
patients who died suddenly or within the first hours of the 
postoperative period as a consequence of a documented 
acute myocardial infarction (AMI). At autopsy, which I 
usually performed with the members of the pathology 
department, I was not able to circumscribe the area of the 
infarction macroscopically. Not even by means of routine 
microscopy was it possible to define the acutely infarcted 
area. Electron microscopy showed afterward that most of 
the cells were intact. 
In 1966, Cox et al. (1) demonstrated by dehydrogenase 
staining techniques that 6 h after ligation of the anterior 
descending branch of the left coronary artery, only ischemia 
was detected in areas exhibiting evidence of pathologic 
change. In 1968, a complete detailed report confirmed the 
preliminary results (2). Meanwhile, the contributions of  
Braunwald and Sonnenblick (3-7) elucidated the physiopa- 
thology of the ischemic myocardium. Clearly, survival of  
myocardial cells was related to oxygen consumption. 
An overview of the knowledge acquired by that time was 
carefiaUy summarized in the article reviewed here (8). The 
definite limitations of the medical treatment available in 
those years were also emphasized (8): 
The development of direct coronary artery bypass graft 
(CABG) by the saphenous vein graft technique has for the 
first time provided a method that immediately increases 
myocardial oxygen supply. As a result, the evolution of the 
area of AMI no longer depends only upon myocardial 
oxygen consumption. These fundamental principles led the 
Cleveland Clinic team to perform emergency operations 
upon patients with acute coronary insufficiency. 
My clinical experience started in April 1968. The first 
patient was described in detail in one of my publications (9). 
Despite the new facilities, we continued to have a waiting 
fist. Those patients with critical obstructive lesions were 
lodged generally in the Bolton Square Hotel and were 
operated on as soon as possible. 
I usually arrived at the Clinic at 7 a.m. One day in April 
1968 the resident on call told me that one of the patients 
had experienced severe chest pain at 6 a.m. and was in poor 
condition. This patient's previous coronary arteriogram had 
shown a severe lesion near the beginning of his left anterior 
descending artery. We went to his room at the hotel and 
found him to be cold and sweating, slightly cyanotic and 
breathing rapidly and with difficulty. His arterial pressure 
was low. Given his previous history, we were certain that he 
was experiencing an AMI, which was confirmed by the 
electrocardiogram. 
While the patient was on his way to the coronary unit, I 
went to B10. Fortunately, Sones had arrived by then and I 
proposed the possibility of performing an emergency oper- 
ation, because the patient had been referred to him for 
cinecoronary angiography. As usual, his love and respect for 
his patients caused him to raise some objections which I 
refuted, telling him of my own observations and reviewing 
the published experimental work. My enthusiasm proved to 
be stronger than his objections, and he accepted my pro- 
posal. 
When the patient had been transferred to the sixth floor 
I explained the situation to his family, who accepted the 
decision to operate. As in so many emergencies, the whole 
team moved quickly and we had him on extracorporeal 
circulation in a few minutes. On opening the pericardium 
we could see that the anterolateral wall of the left ventricle 
did not contract; the ventricle appeared to be distended and 
somewhat cyanotic. It was necessary to decompress the 
heart as soon as possible, so we gently placed a medium- 
sized catheter into the left ventricle by way of the right 
upper pulmonary vein and continuously aspirated the arriv- 
ing blood. 
In the light of past experience we made a bypass from the 
aorta to the anterior descending artery, and we could see 
how the wall of the left ventricle gradually recovered its 
color and contractility. We kept the patient on extracorpo- 
real circulation, with his ventricle undergoing decompres- 
sion for half an hour. His heart began to contract vigorously 
and we gradually reduced the flow from the pump until his 
ventricle was maintaining the entire flow by itself. The 
blood pressure showed constant improvement and it was not 
necessary to administer medication. On the following day 
the patient was extubated. The electrocardiogram showed 
only a minimal alteration in the anterior wall." 
In 1970, I summarized our early experience in Chapter 10 of 
one of my books (10). The paper reviewed here was 
accepted in July 1971, shortly after my return to Argentina 
from the U.S. In this article, 29 patients were analyzed; 18 
operations were performed among patients with impending 
AMI  within the first 24 h, and 11 operations were per- 
formed on patients with AMI .  Twenty-eight years later, the 
accuracy of the conclusions till surprises me. These con- 
clusions were the outcome of our analysis of a very short 
series; over time, they were proved right, so they appear to 
be, in fact, the corollary of many years of practice. 
In the period immediately following publication of this 
article, a number of contributions appeared that indicated 
that the operation could be performed with low operative 
mortality and good clinical results (11-20). The Spokane 
group (DeWood et al.) accumulated the largest experience 
(21-25). DeWood et al. (26) presented a complete report of 
387 patients (200 on medical treatment and 187 who 
underwent emergency coronary artery bypass graft surgery 
[CABG]) with a hospital mortality of 11.5% versus 5.8% in 
the medical and surgical groups, respectively. I f the opera- 
tion were performed <6 h, the mortality was only 2%. The 
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10-year follow up demonstrated a 41% mortality rate in the 
medically treated group versus a 27% mortality rate in the 
surgical group. 
We continued our efforts in Buenos Aires. Experiments 
with monkeys (27) confirmed that within 6 h, most of the 
myocardial muscle could be reconstructed if the blood 
supply were re-established. Before 1983, 583 patients were 
studied with cinecoronary angiography in the acute and 
subacute phase. These studies again confirmed that coro- 
nary arteries can be visualized in an emergency procedure 
following the original contribution of Begg et al. (28). In 
1977, we first presented a description of the cinecoronary 
angiogram in patients with post-AMI angina (29). This 
description clarified proper surgical indications, and a de- 
tailed analysis of the surgical experience was presented in
another of my publications (30). 
Three decades of progress. The introduction of fibrino- 
lyfic agents has opened anew era in the treatment ofAMI. 
The results of early clinical and randomized trials and 
subsequent large-scale randomized trials demonstrated that 
when intravenous thrombolytic therapy is administered 
within 12 h after onset of symptoms, hospital mortality is 
reduced and survival advantages persist. Late mortality is 
low, particularly when compared with series before the use 
of thrombolyfic agents (31). Nevertheless, it has become 
clear that even with the best regimen, early true reperfusion 
(Thrombolysis in Myocardial Infarction, TIMI, flow 3) 
occurs in a disappointingly low percentage of patients 
(-50%). 
It is a mistake to report TIMI 2 and TIMI 3 flow 
together because TIMI 2 flow should be considered an 
inadequate r sult of therapy (32-36). The European Coop- 
erative Study Group (34) showed that at five years, patients 
with TIMI 2 flow had a mortality incidence similar to that 
of those with TIMI 0 and 1 flow. 
The incidence of recurrent ischemic events reinfarcfion 
and reocclusion after thrombolysis remains high. It is hoped 
that molecular biology and genetic engineering will contrib- 
ute to a new generation of thrombolytic agents (reteplase, 
staphylokinase, t-PA-scu-PA chimera, bat-t-PA, TNK 
mutant, antibody-targeted plasminogen activators and an- 
tibody targeting of adjunctive agents) that will improve our 
present results. Recently, GUSTO III angiographic results 
have shown that reteplase (r-PA) achieved better early 
patency than alteplase (t-PA) but that r-PA was associated 
with an increased probability of late reocclusion (37). 
It is possible that the combination of potent inhibitors of 
the platelet glycoprotein IlbfllIa receptor (38) and throm- 
bolytics will increase the degree of lysis and lessen rethrom- 
bosis. The result of the TLMI 14 trial showed that TIMI 3 
flow increased to 76% when abciximab was administered 
with t-PA (60-min infusion) (39). The CABG has also 
been used after thrombolysis for AMI. Several publications 
confirming its use appeared in the early- and mid-1980s 
(40-42). An important article was pubfished in 1995: the 
TIMI II Phase II Trial (43). 
A review of all the publications about these advances 
indicates the following: 
1) Intravenous thrombolytic therapy for evolving AM] is 
associated with a significant increase in subsequent 
coronary revascularization when compared with patients 
receiving conventional therapy (44-46); 
2) The CABG can be performed on patients at high risk 
with acceptable operative mortality (except in emergency 
situations) within the first 24 h. Most of the patients in 
the emergency group are in poor hemodynamic condi- 
tion and many are in cardiogenic shock. In the TIM1 
population, 58% required an intraaortic balloon. Re- 
cently, analysis of the SHOCK (SHould we emergently 
revascularize Occluded Coronaries for cardiogenic 
shocK) trial registry (47) demonstrated that the combi- 
nation of thrombolytic therapy, intraaortic balloon coun- 
terpulsation, CABG and percutaneous transluminal cor- 
onary angioplasty (PTCA) decreased the mortality of 
this high-risk group of patients to 46.9%; and 
3) Blood loss is greater when CABG is performed on 
patients receiving thrombolytic agents, particularly if 
surgery is performed uring the first 24 h, when hem- 
orrhagic events and reoperations are common. For this 
reason, the cooperation of an expert in coagulation 
therapy is mandatory in the operating room and in the 
immediately postoperative r cuperation. 
The use of PTCA in AMI increased significantly after the 
report of the PAMI trial in 1993 (48), which compared the 
results of primary PTCA with those of thrombolytic ther- 
apy for AMI. Several publications, including a critical 
analysis reported by Michels and Yusuf (49), demonstrated 
a significant reduction in mortality with PTCA. When 
PTCA was compared with thrombolytic therapy, PTCA 
resulted in smaller infarct size and better preserved left 
ventricular function. Unfortunately, although it reduced the 
incidence of recurrent angina, reinfarction and reocclusion, 
the incidence of these factors till remained high in PTCA 
patients (50). Furthermore, the incidence of restenosis i
also high. Horrigan et al., in a recta-analysis of860 patients, 
found that average incidence of restenosis after PTCA was 
43% (51). 
In later eports (although with smaller series of patients), 
it was shown that stents can be used after PTCA in patients 
with AMI with a high success rate (52-61). The results of 
the multicenter PAMI Stent Pilot Study confirmed those of 
earlier contributions. Follow up at six months (62) demon- 
strated that in a comparison between 452 patients treated 
with heparin-coated stents versus 448 patients treated with 
PTCA alone, the addition of stents resulted in greater 
luminal diameter; educed angiographic restenosis (16.9% 
vs. 35.9%); and also reduced combined end point of death, 
recurrent AMI, disabling stroke and target-vessel revascu- 
larization due to postprocedural angina or ischemia (12.4% 
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vs. 20.1%). Nevertheless, tents cannot be applied in all 
patients, mainly because the arterial diameter must be 
~2.5 mm. In the PAMI Stent Pilot Study, 31% of the 
patients were considered ineligible for stent placement "if 
they had small vessels (diameter <2.75 mm), if >2 stents 
were required, if there was a huge residual thrombus, if there 
was a possibility that a stent would be needed in the ostium 
of the left anterior descending coronary artery or left circum- 
flex, if major side branches were in jeopardy, or if delivery or 
expansion of the stem might not be feasible (62)." 
Treating AMI 30 Years Later. It is clear that today, 
patients with AMI can be treated with thrombolysis, PTCA 
or CABG. As is the case with many other issues in 
inedicine, opinions on the appropriate use of alternative 
modalities are divided. On the basis of a critical analysis of 
the guidelines for the management of patients with AMI 
(63) and knowledge acquired throughout the years, I outline 
a number of suggestions for the proper treatment of patients 
with AMI as follows: 
1) A clinical examination of the A.MI patient that only 
takes a few minutes gives us important information. We 
know that infarct-related mortality increases with age, 
female gender, a history of chronic angina, previous 
infarction, hypertension, diabetes and presence of pe- 
ripheral vascular disease (64-68). Significant tachycardia 
(>100 per min), hypotension, signs of congestive heart 
failure, atrial and ventricular arrhythmia, persisting an- 
gina and persisting ST segment depression i dicate that 
patients in this category are at high risk. The TIMI 
Phase II coinvesfigators (69) analyzed the presence of 
eight risk factors before thrombolytic therapy was ad- 
ministered: age >70 years, female gender, a history of 
diabetes mellitus or previous AMI, electrocardiographic 
evidence of evolving anterior infarction or atrial fibrilla- 
tion, evidence on physical examination of mild pulmo- 
nary congestion, hypotension (systolic pressure 
<100 mm Hg) and sinus tachycardia (heart rate >100 
beats/min). Among 3,261 patients, 864 presented 0 risk 
factors and the mortality rate at six weeks was only 1.5%; 
for those who presented one risk factor, mortality was 
2.3% (1,384 patients); for two risk factors, 7% (689 
patients); for three risk factors, 13% (231 patients); and 
>4 risk factors, 17.2% (93 patients). Therefore, clinical 
examination and the presence of risk factors, which are 
easy to remember and do not have a numeric score 
(70,71), can clearly categorize patients at low and high 
risk. A 12-lead electrocardiogram for primary screening 
wi.1/differentiate b tween the groups. 
2) Echocardiograms in the emergency room are mandatory. 
The contribution of Sabia et al. (72,73) demonstrated 
that regional wall motion abnormalities (RWMA) car- 
ried out with two-dimensional echocardiography in- 
crease the diagnostic yield for AMI. Although the 
finding of RWMA cannot differentiate between isch- 
emia and necrosis, it can define the extent of myocar- 
3) 
4) 
dium involved and provide information of the myocar- 
dium remote from the region of acute injury. The 
analysis of the left ventricular systolic dysfunction 
(LVSD) can help cardiologists predict events within 
48 h of admission (73). Events occur in 26.9% of the 
patients when LVSD is present, versus 3.3% when 
LVSD is absent. 
The laboratory also plays a role in establishing the final 
diagnosis. Rapid blood bedside assays of cardiac specific 
tropomin T (cTnT) and I (cTnI) are now available. 
Balloon-flotation right-heart catheter monitoring with 
measurement ofpulmonary capillary wedge pressure and 
cardiac output is very helpful in patients with early signs 
of left ventricular deterioration. Of  course, its use is 
mandatory in patients with cardiogenic shock. 
As a consequence of this analysis (Fig. 1), patients at high 
risk should be sent directly to the cardiac laboratory for 
emergency cinecoronary angiography. After carefully re- 
viewing the study, most patients will be treated with PTCA 
and a stent. Nevertheless, patients with severe left main 
coronary artery trunk obstruction, left main equivalent or 
three severe proximal obstructions hould be sent for 
CABG. It is important to remember that survival after AMI 
is determined by the infarct size and the capacity of remote, 
nonischemic myocardium to support he systemic ircula- 
tion by hypercontractility (74). A recent report byJaarsma et 
al. (75) showed a 69% mortality rate for patients who did 
not have remote hypercontractility, and a previous contri- 
bution by Schuster and BuUdey (76) reported a 72% late 
mortality rate for patients with "ischemia t a distance." Of  
course, patients with cardiogenic shock should be sent 
immediately to the cardiac laboratory (after insertion of an 
intraaortic balloon). The PTCA procedure is at the front- 
line to reduce the extremely high mortality rate. 
Patients in the low risk category with ST segment 
elevation or left bundle branch block who have no contra- 
indications hould be treated with intravenous thrombolytic 
therapy. Their evolution should be followed closely because 
the preliminary stratification can change within a few hours. 
Early discharge after thrombolytic therapy can be accom- 
plished in low risk patients with uncomplicated AMI, but a 
submaximal test (five metabolic equivalents [METs]) is 
indicated before discharge in patients who can exercise. 
Patients with a positive test should be sent to the cardiac 
laboratory where the decision for the most suitable treat- 
ment can be made. 
Patients who cannot exercise may be investigated (with 
caution) by pharmacologic thallium-201 or dipyridamole 
echo, or they may be sent directly to the cardiac laboratory. 
They represent 10% to 22% of survivors of AMI. Such 
patients have a high mortality rate and a high incidence of 
recurrent events (77-81). Between three and six weeks later, 
an exercise test (full Bruce protocol with or without 
thallium-201) or exercise chocardiography should be per- 
formed. As many as 35% of patients with a negative 
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Hguro 1. Present approach to acute myocardial infarction. MT = medical treatment; PTCA = percutaneous transluminal coronary 
angioplast3q, CABG = coronary artery bypass graft. 
predischarge submaximal exercise test may provide vidence 
of myocardial ischemia on a more strenuous testing (82,83). 
Patients with negative tests are followed under medical 
treatment (mortaLity at one year <2%) (84-87); patients 
with positive tests should be sent for catheterization (mor- 
tality at one year is as high as 15%) (85). Recurrent ischemic 
events are always a clear indication for cinecoronary angiog- 
raphy. Patients with unsuccessful orcomplicated PTCA will 
require CABG. 
Both PTCA and CABG can work together for the 
benefit of patients during the early days after of AMI. In 
patients with multivessel disease, PTCA and stenting can be 
done first at the culprit lesion. A few clays later, when the 
enzymes are close to normal evels, multiple CABGs can be 
performed without increasing the operative risk. This 
double-step procedure has been applied in our institute for 
the past three years. 
Naturally, it is understood that a significant number of 
patients will be kept in medical treatment. Approximately 
33% of U.S. patients with AM_I received thrombolytic 
therapy. The analysis of the NRMI showed that early 
preliminary PTCA was performed in 5.9% of the patients; 
emergency CABG was used in 0.6%. During hospitaliza- 
tion, 20.5% and 18.8% underwent PTCA and CABG, 
respectively (Rogers, WJ, personal communications No- 
vember 1996). In the GUSTO trial (88,89), 72% of 21,772 
patients underwent angiography before discharge and of 
those, 59% underwent revascularization (70%, PTCA; 30%, 
CABG). The TIMI IIIB trial (90) presented similar esults: 
out of the conservative strategy group (733 patients), 64% 
had catheterization within six weeks. Revascularization was 
performed in 49% (PTCA in 26% and CABG in 23%). 
These three trials can give us a general idea of the present 
approach for patients with AMI. 
CONCLUSION 
In conclusion, PTCA and thrombolysis are at the front 
llne for emergency treatments in most of the patients with 
AMI. Coronary artery bypass graft is indicated in a small 
number of patients within the first 24 h. However, the number 
of operations increases ignificantly in the following weeks. 
The progress that has been made in the therapy of AMI 
over the 28 years since the publication of the first article 
documenting the efficacy of CABG is a great example of the 
convergence of a variety of research fields treating a com- 
mon clinical problem. I am pleased to see that at present the 
devastating effects of AMI have been ameliorated by the 
combined efforts of the clinician, the interventional cardi- 
ologist and the cardiovascular surgeon. 
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